Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that parents of women with PCOS have a higher prevalence of insulin resistance and Type II diabetes than parents of healthy women.

This study found no association between the type of baldness, stress levels, and smoking status among male residents of Lahore.

Hair loss in women is common, starts in late 20s, and affects 30% of women over 50.

In this study, researchers found that the existing Norwood and Hamilton classifications for androgenetic alopecia in Indian males had significant limitations, with 18% of cases not fitting into existing pattern categories.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study observed that female androgenetic alopecia is common among Caucasian women, starting in the late 20s and peaking after age 50.

This article reviews androgenic disorders in women, such as PCOS, highlighting how understanding these conditions could improve their management, but it presents no new clinical findings.

This study suggests that beard dermal papilla cells may produce androgen-dependent growth factors that stimulate keratinocyte proliferation, while frontal scalp cells can have an inhibitory effect mediated by TGF-β1.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This retrospective study examined the prevalence and severity of androgenetic alopecia in dermatology outpatients, identifying factors associated with its development.

This study found that STAT3 signaling is essential for initiating the hair growth phase but not involved in hair follicle development during the fetal period.

The abstract reports no new clinical results; it describes finasteride’s mechanism of action in androgenetic alopecia and mentions unpublished trial results by the manufacturer and investigators.

This study found that Sophora flavescens extract may promote hair growth in mice by inducing earlier hair cycle changes and regulating growth factors in dermal papilla cells.

This study found that after oral administration of finasteride in healthy volunteers, the drug was extensively metabolized, with the majority being excreted as metabolites in urine and feces.

New mutations in hair keratin genes cause the rare hair disorder monilethrix.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This study observed an increasing trend of young patients with androgenetic alopecia visiting dermatologists, with genetic factors and abnormal androgen metabolism in the scalp contributing to its development.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

Botulinum toxin-A injections in the scalp can reduce hair loss and promote new hair growth in men with certain types of baldness.

The authors concluded that finasteride treatment inhibits hippocampal neurogenesis in mice, potentially impacting emotional behaviors and contributing to the pathophysiology of affective disorders.

This study reported that a novel cell culture medium gel significantly increased hair counts and reduced hair loss in men with androgenetic alopecia over a six-month period.

This study found that 58% of men aged 30-50 had androgenic alopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.

This article describes the potential applications of myoblast implantation for muscle regeneration and its promising social and economic value but reports no new clinical results.

This study found that a high proportion of androgenetic alopecia patients were young individuals with mild types, potentially due to psychological stress in social situations.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.